Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
46 hedge funds and large institutions have $25M invested in Sorrento Therapeutics, Inc. in 2017 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 29 closing their positions.
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
44% more call options, than puts
Call options by funds: $13K | Put options by funds: $9K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
28% less funds holding
Funds holding: 64 → 46 (-18)
52% less capital invested
Capital invested by funds: $52.5M → $25M (-$27.5M)
59% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.1M |
| 2 |
IP
Intellectus Partners
San Francisco,
California
|
+$956K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$760K |
| 4 |
Goldman Sachs
New York
|
+$490K |
| 5 |
ECM
Element Capital Management
New York
|
+$429K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$2.08M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$1.51M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$1.14M |
| 4 |
State Street
Boston,
Massachusetts
|
-$975K |
| 5 |
VIA
Vident Investment Advisory
Alpharetta,
Georgia
|
-$674K |
SRNE Hedge Fund Activity: Q2 2017 in Review
46 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q2 2017, worth a combined $25M — down 52% from $52.5M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of SRNE and 12 opened new positions — a net loss of 17 holders — while 7 trimmed existing stakes and 18 added.
The largest buyer was Millennium Management, adding an estimated $1.1M. The largest seller was BlackRock, cutting an estimated $2.08M.
- 46 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q2 2017, down from 64 in Q1 2017.
- Funds reported $25M of Sorrento Therapeutics, Inc. stock for Q2 2017, down 52% quarter-over-quarter.
- 12 funds opened new Sorrento Therapeutics, Inc. positions in Q2 2017 and 29 closed out, a net change of -17 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q2 2017 was Millennium Management, an estimated $1.1M added.
- The largest Sorrento Therapeutics, Inc. seller in Q2 2017 was BlackRock, an estimated $2.08M sold.
Based on aggregated 13F filings for Q2 2017.